Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Granexin by Xequel Bio for Radiodermatitis: Likelihood of Approval
Granexin is under clinical development by Xequel Bio and currently in Phase III for Radiodermatitis. According to GlobalData, Phase III...